{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT05859464",
      "orgStudyIdInfo": {
        "id": "ZL-1218-001"
      },
      "secondaryIdInfos": [
        {
          "id": "KEYNOTE-F22, MK-3475-F22",
          "type": "OTHER",
          "domain": "Merck Sharpe & Dohme, LLC"
        }
      ],
      "organization": {
        "fullName": "Zai Lab (Hong Kong), Ltd.",
        "class": "INDUSTRY"
      },
      "briefTitle": "A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors",
      "officialTitle": "A Phase I, Open-label, Multicenter Study of ZL-1218 as a Single Agent and as Combination Therapy With Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumor Malignancies"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-01",
      "overallStatus": "TERMINATED",
      "whyStopped": "Sponsor Decision",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2023-07-24",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2025-08-28",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2025-08-28",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2023-03-17",
      "studyFirstSubmitQcDate": "2023-05-04",
      "studyFirstPostDateStruct": {
        "date": "2023-05-16",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-10-14",
      "lastUpdatePostDateStruct": {
        "date": "2025-10-20",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Zai Lab (Hong Kong), Ltd.",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Zai Biopharmaceutical (Shanghai) Co., Ltd.",
          "class": "UNKNOWN"
        },
        {
          "name": "Merck Sharp & Dohme LLC",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies."
    },
    "conditionsModule": {
      "conditions": [
        "Malignant Solid Tumor"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 34,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Part 1: Dose Escalation; ZL-1218",
          "type": "EXPERIMENTAL",
          "description": "Drug: ZL-1218 ZL-1218 dose escalation",
          "interventionNames": [
            "Drug: ZL-1218"
          ]
        },
        {
          "label": "Part 1: Dose Escalation; ZL-1218 in combination with Pembrolizumab",
          "type": "EXPERIMENTAL",
          "description": "Drug: ZL-1218 ZL-1218 dose escalation\n\nDrug: Pembrolizumab (KEYTRUDA®) Combination treatment with ZL-1218",
          "interventionNames": [
            "Drug: ZL-1218",
            "Drug: Pembrolizumab"
          ]
        },
        {
          "label": "Part 2: Cohort Expansion; Prior CPI Therapy",
          "type": "EXPERIMENTAL",
          "description": "Drug: ZL-1218 ZL-1218 recommended dose\n\nDrug: Pembrolizumab (KEYTRUDA®) Combination treatment with ZL-1218",
          "interventionNames": [
            "Drug: ZL-1218",
            "Drug: Pembrolizumab"
          ]
        },
        {
          "label": "Part 2: Cohort Expansion; CPI therapy Naive",
          "type": "EXPERIMENTAL",
          "description": "Drug: ZL-1218 ZL-1218 recommended dose\n\nDrug: Pembrolizumab (KEYTRUDA®) Combination treatment with ZL-1218",
          "interventionNames": [
            "Drug: ZL-1218",
            "Drug: Pembrolizumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "ZL-1218",
          "description": "ZL-1218 dose escalation",
          "armGroupLabels": [
            "Part 1: Dose Escalation; ZL-1218",
            "Part 1: Dose Escalation; ZL-1218 in combination with Pembrolizumab",
            "Part 2: Cohort Expansion; CPI therapy Naive",
            "Part 2: Cohort Expansion; Prior CPI Therapy"
          ]
        },
        {
          "type": "DRUG",
          "name": "Pembrolizumab",
          "description": "Combination treatment with ZL-1218",
          "armGroupLabels": [
            "Part 1: Dose Escalation; ZL-1218 in combination with Pembrolizumab",
            "Part 2: Cohort Expansion; CPI therapy Naive",
            "Part 2: Cohort Expansion; Prior CPI Therapy"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Incidence of Dose Limiting Toxicities",
          "description": "Number of subjects with dose limiting toxicities (DLTs) through dose escalation only.",
          "timeFrame": "Approximately 24 months"
        },
        {
          "measure": "Incidence of Treatment Emergent Adverse Events",
          "description": "Number of subjects with treatment-emergent adverse effects through dose escalation and expansion.",
          "timeFrame": "Approximately 24 months"
        },
        {
          "measure": "Incidence of Serious adverse events",
          "description": "Number of subjects with Serious Adverse Events through dose escalation and expansion.",
          "timeFrame": "Approximately 24 months"
        },
        {
          "measure": "Clinically Significant changes in safety assessments",
          "description": "Changes in safety assessment parameters (e.g., vital signs, electrocardiograms \\[ECGs\\], and clinical laboratory results) through dose escalation and expansion.",
          "timeFrame": "Approximately 24 months"
        },
        {
          "measure": "ORR per RECIST 1.1",
          "description": "Objective Response Rate (ORR) per RECIST 1.1 through dose expansion only.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "ORR per iRECIST",
          "description": "Objective Response Rate per iRECIST through dose expansion only.",
          "timeFrame": "up to 24 months"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "ORR per RECIST 1.1",
          "description": "Objective Response Rate (ORR) per RECIST 1.1 through dose escalation only.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "ORR per iRECIST",
          "description": "Objective Response Rate (ORR) per iRECIST through dose escalation only.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Duration of Response per RECIST 1.1",
          "description": "Duration of Response per RECIST 1.1 through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Duration of Response per iRECIST",
          "description": "Duration of Response per iRECIST through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "PFS per RECIST 1.1",
          "description": "Progression-Free Survival (PFS) per RECIST 1.1 through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "PFS per iRECIST",
          "description": "Progression-Free Survival (PFS) per iRECIST through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "DCR per RECIST 1.1",
          "description": "Disease Control Rate (DCR) per RECIST 1.1 through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "DCR per iRECIST",
          "description": "Disease Control Rate (DCR) per iRECIST through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Overall Survival",
          "description": "Overall Survival (OS) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Pharmacokinetics (PK): AUC",
          "description": "Area under curve (AUC) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Pharmacokinetics (PK): Cmax",
          "description": "Maximum serum concentration (CMax) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Pharmacokinetics (PK): Tmax",
          "description": "Time to reach Cmax (Tmax) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Pharmacokinetics (PK): Ctrough",
          "description": "Ctrough through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Pharmacokinetics (PK): Vss",
          "description": "Volume of distribution as steady state (Vss) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Pharmacokinetics (PK): CL",
          "description": "Clearance (CL) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Pharmacokinetics (PK): t1/2",
          "description": "Half-life (t1/2) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Immunogenicity",
          "description": "Incidence of anti-drug antibodies (ADAs) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        },
        {
          "measure": "Immunogenicity",
          "description": "Quantity of anti-drug antibodies (ADAs) through dose escalation and expansion.",
          "timeFrame": "up to 24 months"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult men and women ≥ 18 years of age. If 18 years is not the age of majority, then adult men and women ≥ age of majority per local regulation.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Life expectancy \\> 12 weeks.\n* Subjects must have histologically confirmed and documented diagnosis of locally advanced unresectable or metastatic advanced solid tumor that is refractory to standard treatment, or intolerant to standard treatment, or for which no standard treatment exists.Subjects must have at least one target lesion as defined by RECIST v1.1 on CT, PET/CT, or MRI scan.\n* Subjects must have a site of disease which is not previously irradiated and is safe and amenable to biopsy per the treating institution's guidelines. Subjects must be willing to undergo a tumor biopsy at screening and on treatment, per the protocol guidelines.\n* Subjects must have a site of disease which is not previously irradiated and is safe and amenable to biopsy per the treating institution's guidelines. Subjects must be willing to undergo a tumor biopsy at screening and on treatment, per the protocol guidelines.\n\nExclusion Criteria:\n\n* Symptomatic or uncontrolled brain metastasis requiring concurrent treatment, inclusive of but not limited to surgery, radiation, and/or corticosteroids.\n* Prior exposure to CCR8 inhibitor (anti-CCR8 antibody) or hypersensitivity to any ingredient of the study drug.\n* Out of range value within 10 days prior to the first dose of study treatment.\n* Subjects have received a live or live-attenuated vaccine within 30 days of planned start of study therapy.\n* Subjects with known history of, or any evidence of active, non-infectious pneumonitis.\n* Impaired cardiac function or clinically significant cardiac disease within the last 3 months before administration of the first dose of the study drug.\n* Treatment with any systemic anti-cancer treatment (including investigational products) within 4 weeks before first dose of study drug.\n* Non-palliative radiotherapy within 2 weeks prior to first dose of study drug or have had history of radiation pneumonitis.\n* Major surgery within 4 weeks of the first dose of study drug.\n* Infections requiring systemic antibiotic therapy.\n* Any medical conditions that would, in the investigator's judgement, prevent the subject's participation in the clinical study due to safety concerns, compliance with the study procedures, or interpretation of the study results.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Zai Lab Site 2005",
          "city": "Irvine",
          "state": "California",
          "zip": "92618",
          "country": "United States",
          "geoPoint": {
            "lat": 33.66946,
            "lon": -117.82311
          }
        },
        {
          "facility": "Zai Lab Site 2007",
          "city": "Detroit",
          "state": "Michigan",
          "zip": "48201",
          "country": "United States",
          "geoPoint": {
            "lat": 42.33143,
            "lon": -83.04575
          }
        },
        {
          "facility": "Zai Lab Site 2001",
          "city": "Hackensack",
          "state": "New Jersey",
          "zip": "07601",
          "country": "United States",
          "geoPoint": {
            "lat": 40.88593,
            "lon": -74.04347
          }
        },
        {
          "facility": "Zai Lab Site 2002",
          "city": "New York",
          "state": "New York",
          "zip": "10029",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Zai Lab Site 2003",
          "city": "Spokane",
          "state": "Washington",
          "zip": "99208",
          "country": "United States",
          "geoPoint": {
            "lat": 47.65966,
            "lon": -117.42908
          }
        },
        {
          "facility": "Zai Lab Site 1002",
          "city": "Hangzhou",
          "zip": "310009",
          "country": "China",
          "geoPoint": {
            "lat": 30.29365,
            "lon": 120.16142
          }
        },
        {
          "facility": "Zai Lab Site 1001",
          "city": "Shanghai",
          "zip": "200123",
          "country": "China",
          "geoPoint": {
            "lat": 31.22222,
            "lon": 121.45806
          }
        },
        {
          "facility": "Zai Lab Site 8005",
          "city": "Barcelona",
          "state": "Barcelona",
          "zip": "8023",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Zai Lab Site 8001",
          "city": "Barcelona",
          "state": "Barcelona",
          "zip": "8035",
          "country": "Spain",
          "geoPoint": {
            "lat": 41.38879,
            "lon": 2.15899
          }
        },
        {
          "facility": "Zai Lab Site 8007",
          "city": "Madrid",
          "state": "Madrid",
          "zip": "28040",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Zai Lab Site 8008",
          "city": "Madrid",
          "state": "Madrid",
          "zip": "28050",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.4165,
            "lon": -3.70256
          }
        },
        {
          "facility": "Zai Lab Site 8004",
          "city": "Pozuelo de Alarcón",
          "state": "Madrid",
          "zip": "28223",
          "country": "Spain",
          "geoPoint": {
            "lat": 40.43293,
            "lon": -3.81338
          }
        },
        {
          "facility": "Zai Lab Site 8003",
          "city": "Seville",
          "state": "Sevilla",
          "zip": "41009",
          "country": "Spain",
          "geoPoint": {
            "lat": 37.38283,
            "lon": -5.97317
          }
        },
        {
          "facility": "Zai Lab Site 8002",
          "city": "Valencia",
          "state": "Valencia",
          "zip": "46009",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.47391,
            "lon": -0.37966
          }
        },
        {
          "facility": "Zai Lab Site 8006",
          "city": "Valencia",
          "state": "Valencia",
          "zip": "46010",
          "country": "Spain",
          "geoPoint": {
            "lat": 39.47391,
            "lon": -0.37966
          }
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-20"
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C582435",
          "term": "pembrolizumab"
        }
      ]
    }
  },
  "hasResults": false
}